Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and RedHill Biopharma Ltd. (NASDAQ:RDHL) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Osmotica Pharmaceuticals plc	274.34M	1.28	6.40M	-0.13	0.00
RedHill Biopharma Ltd.	8.36M	25.56	38.82M	-1.70	0.00

Table 1 highlights Osmotica Pharmaceuticals plc and RedHill Biopharma Ltd.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Osmotica Pharmaceuticals plc and RedHill Biopharma Ltd.

	Net Margins	Return on Equity	Return on Assets
Osmotica Pharmaceuticals plc	-2.33%	0%	0%
RedHill Biopharma Ltd.	-464.35%	0%	0%

Analyst Recommendations

The next table highlights the given recommendations and ratings for Osmotica Pharmaceuticals plc and RedHill Biopharma Ltd.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Osmotica Pharmaceuticals plc	0	0	0	0.00
RedHill Biopharma Ltd.	0	0	1	3.00

Competitively the consensus target price of RedHill Biopharma Ltd. is $16, which is potential 112.48% upside.

Institutional and Insider Ownership

Institutional investors held 51.5% of Osmotica Pharmaceuticals plc shares and 29.11% of RedHill Biopharma Ltd. shares. About 42.7% of Osmotica Pharmaceuticals plc’s share are held by insiders. On the other hand, insiders held about 19.1% of RedHill Biopharma Ltd.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Osmotica Pharmaceuticals plc	0.84%	-8.42%	5.43%	0%	0%	-7.35%
RedHill Biopharma Ltd.	-1.67%	-7.59%	-6.35%	2.68%	19.47%	38.2%

For the past year Osmotica Pharmaceuticals plc has -7.35% weaker performance while RedHill Biopharma Ltd. has 38.2% stronger performance.

Summary

Osmotica Pharmaceuticals plc beats RedHill Biopharma Ltd. on 6 of the 9 factors.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. Its clinical-stage pipeline includes TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two European Union member states under the European Decentralized Procedure. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.